McKesson Corporation — ranked No. 1 on MDM’s 2025 List of Top Pharmaceuticals & Healthcare Distributors — announced changes to its reportable segments and organizational structure. Effective with the company’s 2026 fiscal second quarter that began July 1, the new structure enhances strategic alignment and transparency, supporting optimizing portfolio management to drive sustainable long-term value creation for shareholders, said McKesson.

“McKesson has a long history of leadership in healthcare, continuously evolving to meet the needs of our customers, providers, and the patients we collectively serve,” said Britt Vitalone, chief financial officer. “This updated reporting structure reflects a strategic evolution of our business – accelerating growth in the high-margin areas of oncology, multispecialty, and biopharma services. It enhances transparency and reinforces our disciplined approach to capital allocation and shareholder value creation.”

The new reportable segments are:

• North American Pharmaceutical: A newly reportable segment combining McKesson’s scaled wholesale drug distribution businesses in the United States and Canada. It distributes to a broad customer base, including retail and community pharmacies and institutional healthcare providers.
• Oncology and Multispecialty: A newly reportable segment that includes a portfolio of integrated solutions across oncology and multispecialty providers and solutions. The segment includes specialty provider solutions, including distribution-related capabilities, such as specialty drug distribution and group purchasing organizations; and Practice management services supporting the largest physician-led, community-based oncology networks. The segment also includes other multispecialty providers, including retina and ophthalmology, and offers clinical trial services, specialty pharmacy solutions, and access to research, along with innovation through technology-driven insights.
• Prescription Technology Solutions: Connects patients, pharmacies, providers, pharmacy benefit managers, health plans and biopharma through scaled, differentiated networks, improving medication access and affordability, while delivering measurable value to biopharma.
• Medical-Surgical Solutions: Delivers medical-surgical supply distribution, logistics and other related services to healthcare providers across alternate sites of care. This past May, McKesson announced its plan to separate this segment into an independent company.
• Other: Distribution and retail operations in Norway. On Aug, 4, McKesson entered into an agreement to sell its businesses in Norway. The transaction is subject to customary closing conditions.

For fiscal year 2025 ending March 31, McKesson reported annual revenue of $359 billion, up 16%; a net profit of $4.2 billion that increased 15%; and EBITDA of $5.6 billion that rose 11.3%